Can memantine prevent memory impairment induced by MDMA in humans.

Randomised design not specified in registry; double-blind, placebo-controlled four-way crossover in recreational MDMA users. Subjects receive memantine 20 mg or placebo, and 2 hours later receive MDMA 75 mg or placebo, with at least a one-week washout between sessions (4 sessions total).

Primary outcome is memory performance measured immediately after each treatment using verbal and prospective memory tests. Secondary measures include event-related potentials (P300) and perceptual/speech analyses.